IQVIA (IQV) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
27 Feb, 2026Executive summary
Achieved $16.3B in revenue for 2025, up 5.9% from 2024, with Adjusted EBITDA of $3.8B and Free Cash Flow of $2.1B, despite macroeconomic and industry headwinds.
Invested $1.8B in strategic acquisitions and returned $1.2B to shareholders via share repurchases; refinanced over $6B in debt, strengthening capital structure.
Recognized for innovation and leadership, including top rankings in Fortune, TIME, and Forbes, and multiple industry awards for AI, talent development, and sustainability.
Maintained favorable attrition rates (10.5%), high employee engagement, and advanced AI upskilling initiatives with over 230,000 employee engagements.
Voting matters and shareholder proposals
Board recommends FOR all director nominees, executive compensation (say-on-pay), ratification of PricewaterhouseCoopers LLP as auditor, and the 2026 Incentive and Stock Award Plan.
Board recommends AGAINST a shareholder proposal to require an independent Board Chairman, citing flexibility and strong governance as reasons.
Board of directors and corporate governance
Board is 89% independent, with annual elections and a Lead Independent Director; all committees are fully independent.
Recent board refreshment includes the addition of Nobel Laureate Dr. William G. Kaelin Jr., addressing shareholder feedback for more scientific expertise.
Enhanced governance practices: majority voting, proxy access, no supermajority requirements, two clawback policies, and prohibition on hedging/pledging.
Active stockholder engagement, with meetings representing 57% of outstanding shares in 2025.
Latest events from IQVIA
- AI adoption, biotech growth, and new acquisitions drive optimism and margin expansion.IQV
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - AI-driven efficiencies and the Cedar Gate acquisition strengthen patient analytics and growth.IQV
Leerink Global Healthcare Conference 20269 Mar 2026 - Board recommends approval of all proposals except separating Chairman and CEO roles.IQV
Proxy Filing27 Feb 2026 - Strong Q4 growth, stable margins, and AI-driven opportunities support a positive outlook.IQV
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Strong 2025 results and 2026 outlook driven by AI, segment realignment, and robust demand.IQV
Q4 20255 Feb 2026 - Q2 revenue and profit margins rose, with record backlog and reaffirmed full-year guidance.IQV
Q2 20243 Feb 2026 - Strong R&DS and data-driven AI offset TAS volatility, supporting robust margins and growth outlook.IQV
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 4.3%, adjusted EPS up 14.1%, with strong TAS growth and $31.1B backlog.IQV
Q3 202417 Jan 2026 - Q3 outperformed on TAS growth, but R&DS bookings faced headwinds from cancellations and delays.IQV
UBS Global Healthcare Conference 202414 Jan 2026